



# CALIFORNIA CONTRACT CITIES ASSOCIATION



## 2025-2026 EXECUTIVE BOARD

**Brenda Olmos**  
*President*  
Paramount

**Dr. John Erickson**  
*Vice President*  
West Hollywood

**Chris Barajas**  
*Secretary*  
Jurupa Valley

**Sal Melendez**  
*Treasurer*  
Montebello

**Jennifer Perez**  
*Immediate Past President*  
Norwalk

**Jeff Wood**  
*Ambassadors*  
Lakewood

**Mark Waronek**  
*Associate Members*  
Lomita

**Cedric Hicks**  
*Budget & Audit*  
Carson

**Margaret Finlay**  
*Bylaws*  
Duarte

**John Moreno**  
*City Managers/ Administrators*  
Paramount

**Victoria Garcia**  
*Legal & Contracts*  
San Fernando

**Gustavo Camacho**  
*Legislative*  
Pico Rivera

**Ed Reece**  
*Legislative Co-Chair/ Director-at-Large*  
Claremont

**Jessica Ancona**  
*Marketing*  
El Monte

**Victor Sanchez**  
*Membership*  
Bellflower

**James Bozajian**  
*Resolutions*  
Calabasas

**Oralia Rebollo**  
*Budget & Audit*  
Commerce

**Yesenia De La Rosa**  
*Special Events*  
Avalon

**Marcel Rodarte**  
*Executive Director*

July 25, 2025

Assemblymember Buffy Wicks  
Chair, Assembly Appropriations Committee  
1021 O Street, Suite 8220  
Sacramento, CA 95814

RE: Senate Bill 6 - SUPPORT

Dear Assemblymember Wicks,

The California Contract Cities Association (CCCA) writes to express our support of SB 6 (Ashby), which makes xylazine, also known as "tranq," a Schedule III drug under California's Uniform Controlled Substances Act.

Xylazine is a veterinary sedative that is unsafe for humans but now commonly being mixed with fentanyl and trafficked. The dangerous combination is connected to a significant increase in overdose deaths nationwide. Unfortunately, xylazine overdoses cannot be treated with naloxone, a medicine typically used to reverse an opioid overdose. As a result, such mixed drug use is one of the deadliest drug threats in the country.

In an effort to ameliorate the opioid epidemic the State continues to face today, it is imperative that the legislature takes proactive measures to limit access to xylazine. The growing use of the drug threatens to exacerbate a crisis that has plagued California communities for far too long. By passing SB 6, California will be able to quickly restrict access to xylazine, protecting the health and well-being of Californians.

CCCA represents 80 cities throughout California. For more than 65 years, CCCA's mission has been to advance the benefits of the contracting model and strengthen local control. With collaborative governance as a focal point, CCCA has advanced its mission through education, advocacy, networking, and legislative access to protect and enhance the quality of life for more than 7.5 million residents. As a matter of policy, our organization supports and defends the rights of cities on policy issues pertinent to them. We thank you in advance for your consideration of our support for SB 6.

Yours in service,

Marcel Rodarte, Executive Director

CC: Members of the Assembly Appropriations Committee